Speedbul schreef op 8 juni 2021 03:40:
Celyad Oncology to Present Data from Phase 1 IMMUNICY-1 Trial of Non-Gene Edited Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress
May 12, 2021 By
No Grade = 3 treatment-related adverse events nor evidence of Graft-versus-Host disease reported from the completed first dose-level (DL1) cohort of Phase 1 dose-escalation IMMUNICY-1 trial evaluating the shRNA-based anti-BCMA CAR T candidate, CYAD-211, for relapsed/refractory (r/r) multiple myeloma
Initial clinical activity observed, with one confirmed partial response (PR) observed in this low dose (30×106 cells per infusion)
EHA 2021 ePoster Presentation Details:
The following abstract published today is now available on the EHA 2021 website. Following the presentation at the meeting, the
posters will be available in the Scientific Publications section of Celyad Oncology’s website.
Title: Objective response at low dose in the first-in-human IMMUNICY-1 trial evaluating non-gene edited allogeneic CYAD-211 antiBCMA
CAR T product in relapsed or refractory multiple myeloma
Presenter: Dr. Sébastien Anguille, Antwerp University Hospital (UZA), Edegem, Belgium
Topic: Gene therapy, cellular immunotherapy and vaccination - Clinical
Date and Time: e-Poster available starting Friday, June 11, 2021 at 9:00 a.m. CEST
Abstract Number: EP739